In Vivo Eradication of a Rituximab-Resistant Human CD20+ B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement

被引：0

作者：

Betting, David J. ^{[1
]}

Kafi, Kamran ^{[1
]}

Yamada, Reiko E. ^{[1
]}

Steward, Kristopher K. ^{[1
]}

Olafsen, Tove ^{[2
]}

Wu, Anna M. ^{[2
]}

van Rooijen, Nico ^{[3
]}

Timmerman, John M. ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA

[3] Vrije Univ Amsterdam, Fac Med, Dept Mol Cell Biol, Amsterdam, Netherlands

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：302 / 302

页数：1

共 50 条

[31] Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In vitro and in Vivo models
Miller, John
Barth, Matthew J.
Mavis, Cory
Tsai, Ping-Chiao
Klener, Pavel, Jr.
Hernandez-Ilizaliturri, Francisco
Czuczman, Myron S.
BLOOD, 2012, 120 (21)
[32] CLINICAL STUDY OF AUTOLOGOUS NATURAL KILLER CELLS COMBINED WITH RITUXIMAB FOR THE TREATMENT OF ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
Cui, J. W.
Li, W.
Bai, O.
Liu, C. S.
Li, D.
Jin, H. F.
HAEMATOLOGICA, 2012, 97 : 319 - 320
[33] Complement activation in circulation and central nervous system after Rituximab (Anti-CD20) treatment of B-Cell lymphoma
Harjunpää, A
Wiklund, T
Collan, J
Janes, R
Rosenberg, J
Lee, D
Grillo-López, A
Meri, S
LEUKEMIA & LYMPHOMA, 2001, 42 (04) : 731 - 738
[34] Establishment of a CD59-deficient follicular lymphoma cell line:: a tool for studying the role of complement in Rituximab-mediated killing of lymphoma cells
Junnikkala, S
Harjunpää, A
Meri, S
MOLECULAR IMMUNOLOGY, 2003, 40 (2-4) : 218 - 219
[35] Genetically engineered natural killer (NK) cell immunotherapy for children poor risk b-cell (CD20+) leukemia and lymphoma (L/L).
Chu, Yaya
Ayello, Janet
Hochberg, Jessica
Van de Ven, Carmella
Murphy, James
Cairo, Mitchell S.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[36] IGM-2323 is a CD20xCD3 IgM bispecific T-cell engager that kills low CD20-expressing and rituximab-resistant B-cell lymphomas
Li, K.
Kotturi, M. F.
Manlusoc, M.
Yun, R.
Hinton, P. R.
Logronio, K.
Baliga, R.
Hernandez, G.
Sinclair, A. M.
Carroll, S. F.
Godfrey, W. R.
Keyt, B. A.
ANNALS OF ONCOLOGY, 2021, 32 : S778 - S779
[37] Rituximab maintenenance therapy in CD20+ B-cell Non-Hodgkin-Lymphoma first results of a multicenter prospective randomised phase II study
Witzens-Harig, M.
Hensel, M.
Schmier, J.
Neben, K.
Benner, A.
Dreger, P.
Kuhn, C.
Schmidt-Wolf, I.
Kramer, A.
Ho, A. D.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 108 - 108
[38] Rituximab activates Syk and AKT in CD20-positive B cell lymphoma cells dependent on cell membrane cholesterol levels
Nozaki, Yumi
Mitsumori, Toru
Yamamoto, Takeo
Kawashima, Ichiro
Shobu, Yuki
Hamanaka, Satoshi
Nakajima, Kei
Komatsu, Norio
Kirito, Keita
EXPERIMENTAL HEMATOLOGY, 2013, 41 (08) : 687 - 696
[39] Biological response of B lymphoma cell lines to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated lysis.
Golay, J
Zaffaroni, L
Vaccari, T
Borleri, GM
Tedesco, F
Dastoli, G
Barbui, T
Rambaldi, A
Introna, M
BLOOD, 1999, 94 (10) : 92A - 92A
[40] Comparison of Lu-177-anti-CD20 (Rituximab) efficacy on human and canine B-cell lymphoma xenografts
Balogh, L.
Mikolajczak, R.
Wojdowska, W.
Mathe, D.
Polyak, A.
Postenyi, Z.
Haasz, V.
Janoki, G.
Thuroczy, J.
Joba, R. Peter
Dabasi, G.
Barra, M.
Bus, K.
Jorgov, L.
Janoki, G. A.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S318 - S319

← 1 2 3 4 5 →